A Novel IgG- and IgM-Cleaving Endopeptidase, IceMG, for Antibody-Mediated Rejection.

ABSTRACT: Antibody-mediated rejection (AMR) remains a significant barrier to successful outcomes in both allo- and xenotransplantation. In this study, we investigate the efficacy of a novel recombinant endopeptidase, IceMG, which simultaneously cleaves IgG and IgM in rhesus macaques sensitized by sequential skin transplantations. A single intravenous dose of IceMG (2mg/kg) induced a significant but transient reduction in total IgG and IgM levels. Allo- and xenoreactive IgG and IgM, measured by T cell and B cell flow crossmatch assay, also reduced significantly but returned to baseline within two weeks. Using a pathogen-specific multiplexed reporter cell panel, NHPs showed a reduction in IgG and IgM responses against SARS-CoV-2 antigens, including the spike protein, RBD-SD1, and S2 domain antigens, f

SUBMITTER: Martinino A 

PROVIDER: S-EPMC12580909 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature